870851P

C16 Carnitine

Avanti Research^™ - A Croda Brand 870851P, powder

• Synonim(y): palmitoyl L-carnitine
• Wzór empiryczny (zapis Hilla): C₂₃H₄₅NO₄
• Numer CAS: 1935-18-8
• Masa cząsteczkowa: 399.61
• Numer MDL: MFCD00152152
• Kod UNSPSC: 12352211
• NACRES: NA.25

Właściwości

• Formularz: powder
• opakowanie: pkg of 1 × 5 mg (870851P-5mg)
• producent / nazwa handlowa: Avanti Research^™ - A Croda Brand 870851P
• typ lipidu: bioactive lipids
• Warunki transportu: dry ice
• temp. przechowywania: −20°C
• ciąg SMILES: C[N+](C)(C)C[C@H](OC(CCCCCCCCCCCCCCC)=O)CC([O-])=O
• InChI: 1S/C23H45NO4/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-23(27)28-21(19-22(25)26)20-24(2,3)4/h21H,5-20H2,1-4H3
• Klucz InChI: XOMRRQXKHMYMOC-UHFFFAOYSA-N

Opis

Opis ogólny

C16 Carnitine, also called as palmitoyl L-carnitine, is an endogenous acylcarnitine. Structurally, it contains Levocarnitine (L-carnitine) head group and 16 carbon saturated fatty acid tail. Palmitoyl L-carnitine is derived by reversible reaction of palmitoyl-CoA esters with carnitine. Palmitoyl L-carnitine is transported across the inner membrane by carnitine palmitoyl transferase II for β-oxidation.

Zastosowanie

C16 Carnitine or palmitoyl L-carnitine has been used to study its influence on the glycine transporters activity.

Działania biochem./fizjol.

C16 Carnitine has a potential to inhibit glycine transporter 2 (GlyT2). It acts as a key energy donor for β-oxidation. Palmitoyl carnitine activates the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum. Elevated levels of palmitoyl L-carnitine due to palmitoyl transferase II deficiency causes autosomal recessive disorder of energy metabolism, which primarily affects skeletal muscle.

Opakowanie

5 mL Amber Glass Screw Cap Vial (870851P-5mg)

Informacje prawne

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Kod klasy składowania: 11 - Combustible Solids
• Klasa zagrożenia wodnego (WGK): WGK 3